Last reviewed · How we verify

NCT04701372

Clinical Outcomes From NOCD Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention

Completed Last updated 8 January 2021
What this trial tests

trial testing Exposure and response prevention therapy in Obsessive-Compulsive Disorder in 2,069 participants. Completed in 8 November 2020.

Timeline
1 January 2020
Primary endpoint
8 November 2020
8 November 2020

Quick facts

Lead sponsorNOCD
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,069
Start date1 January 2020
Primary completion8 November 2020
Estimated completion8 November 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NOCD

Who can join

10 and older, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a naturalistic, observational study of individuals with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy, augmented with between-session support with text messaging and an online community forum.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Exposure and response prevention therapy

Trials testing the same drug.

Other recruiting trials for Obsessive-Compulsive Disorder

Currently open trials in the same condition.

Other NOCD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04701372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing